Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-701 in recurrent glioblastoma
NCT02078648Phase 2Completed
- Sponsor
- Stemline Therapeutics
- Start
- May 2014
- Primary completion
- Sep 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SL-701 in glioblastoma multiforme (GBM), sponsored by Stemline Therapeutics. Started May 2014; status: completed.
02
Drugs
SL-701
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02078648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078648.